Show Summary Details
Page of

Haemopoietic stem cell disorders 

Haemopoietic stem cell disorders

Haemopoietic stem cell disorders

D.C. Linch

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2015. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy).

date: 23 April 2017

The term stem-cell disorder is usually understood to imply that a disease process has begun in a primitive cell with the potential to develop into cells of different lineages. Difficulties with such a definition include (1) malignant change in a very primitive cell does not necessarily lead to the production of mature cells of multiple lineages; (2) although an immature phenotype of a malignant cell may indicate transformation of a very early cell, it is possible that transformation could arise in a later cell with subsequent dedifferentiation.

Possible stem cell disorders—quantitative and qualitative abnormalities of haemopoietic stem cells could result in one or more of the following: (1) depletion of the stem cell population leading to failure of production of adequate mature progeny; (2) failure of proliferation of a normal number of stem cells also leading to a similar deficiency of end-cells; (3) production of normal numbers of defective end-cells; (4) malignant transformation of stem cells.

A pragmatic approach—the involvement of multiple lineages in a disease process is a ready indicator of a stem cell disorder. Such disorders include (1) myeloproliferative disorders—polycythaemia rubra vera, chronic myeloid leukaemia, myelofibrosis, and various intermediate/transitional forms are characterized by the predominant cell type produced by the malignant clone, but they all involve a primitive stem cell; (2) acute myeloid leukaemia—in adults, red cells and platelets are commonly involved in addition to myeloid cells; (3) aplastic anaemia—by definition refers to involvement of multiple myeloid lineages; (4) paroxysmal nocturnal haemoglobinuria—due to a somatic mutation in the haemopoietic stem cell in the X-linked phosphatidylinositol glycan-A (PIG-A).

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.